Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jul 08, 2022 12:45pm
100 Views
Post# 34811287

RE:RE:Private Placement

RE:RE:Private Placement
toniZ1 wrote: indeed, no good news. But you can't say that if someone is willing to buy for some millions dollars shares he could do that for 0,10 at the stock market. Such a order would never be filled and if you buy without a limit you would probably have to pay for the most shares a much higher price than 0.18. 

Once again, the only thing that counts here is the legal process with Shiseido. If I remember correctly 3 months to go... we will see if Shiseido buys em out for something around 500m, otherwise replicel is done.

So the final act is not that far away anymore...


The only one willing to buy millions of shares at this point is Andrew Schutte.  This PP was a desperate plea for some working capital to kick the can down the road a little further.  At the time it was announced on March 21st the share price was $.20 so $.18 made sense but not now. 

Maybe if some larger buyers were to buy on the open market we could see the share price actually go up rather than the BS we see now where we see virtually no trading.  This is dead in the water until we hear some positive news.  If it is bad news this company could go under very quickly.






<< Previous
Bullboard Posts
Next >>